Reduction of monthly migraine days follow up: 3 months
|
The mean reduction of monthly migraine days was − 4.2 days
|
The mean reduction of monthly migraine days in the intervention group was 2.5 days fewer (3.5 lower to 1.4 fewer)
|
–
|
469(1 RCT)
| ⨁⨁⨁◯MEDIUMa
|
Treatment with Erenumab 70 mg reduces monthly migraine days slightly compared to placebo.
|
Reduction of monthly acute treatment daysfollow up: 3 months
|
The mean reduction of monthly acute treatment days was −1.6 days
|
The mean reduction of monthly acute treatment days in the intervention group was 1.9 days fewer (2.6 fewer to 1.1 fewer)
|
–
|
469(1 RCT)
| ⨁⨁⨁◯MEDIUMa
|
Treatment with Erenumab 70 mg reduces monthly acute treatment days slightly compared to placebo.
|
At least 50% reduction of monthly migraine days follow up: 3 months
|
235 per 1000
|
399 per 1000(303 to 525)
|
RR 1.6985 (1.2908 to 2.2349)
|
469(1 RCT)
| ⨁⨁⨁◯MEDIUMa
|
Treatment with Erenumab 70 mg results in at least 50% reduction of monthly migraine days compared to placebo.
|
Serious adverse events follow up: 3 months
|
25 per 1000
|
31 per 1000(11 to 92)
|
RR 1.2722(0.4340 to 3.7268)
|
471(1 RCT)
| ⨁⨁⨁◯MEDIUMa
|
Treatment with Erenumab 70 mg results in a small unimportant increase of serious adverse event occurrence compared to placebo.
|
Mortalityfollow up: 3 months
|
0 per 1000
|
0 per 1000(0 to 0)
|
not estimable
|
471(1 RCT)
| |
No deaths were observed with treatment with Erenumab 70 mg or placebo
|